The nanomedicine revolution: Part 2: Current and future clinical applications

P and T

Volumn 37, Issue 10, 2012, Pages 582-591

  Ventola, C Lee ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; APREPITANT; ASPARAGINASE MACROGOL; BIOLOGICAL MARKER; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYTARABINE; DAUNORUBICIN; DENILEUKIN DIFTITOX; DOXORUBICIN; FENOFIBRATE; GLATIRAMER; LEUPRORELIN; MACROGOL; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PEMETREXED; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEVELAMER; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNINDEXED DRUG; VERTEPORFIN;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BLADDER CANCER; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BONE MARROW SUPPRESSION; BRAIN INFECTION; BRAIN TUMOR; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; DEMENTIA; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; EARLY DIAGNOSIS; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; KAPOSI SARCOMA; LUNG CANCER; MATERIAL COATING; MEDICAL DEVICE; MEDICAL RESEARCH; MENINGITIS; NANOMEDICINE; NEUROLOGIC DISEASE; OVARY CANCER; RESTENOSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84867914129     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bhaskar S, Tian F, Stoeger T, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010;7:3.
2. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: Current perspective and future promise. Pharmacol Ther 2010;128(2):324-335.
3. Sajja HK, East MP, Mao H, et al. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol 2009;6(1):43-51.
4. Ledet G, Mandal TK. Nanomedicine: Emerging therapeutics for the 21st century. US Pharm 2012;37(3):7-11.
5. Godin B, Sakamoto JH, Serda RE, et al. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci 2010;31(5):199-205.
6. Chhatriwalla AK, Bhatt DL. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year? Circ Cardiovasc Interv 2008;1(3):217-225.
7. Galvin P, Thompson D, Ryan KB, et al. Nanoparticle-based drug delivery: Case studies for cancer and cardiovascular applications. Cell Mol Life Sci 2012;69(3):389-404.
8. Bawa R. Regulating nanomedicine: Can the FDA handle it? Curr Drug Deliv 2011;8(3):227-234.
9. McGrady E, Conger S, Blanke S, Landry BJ. Emerging technologies in healthcare: Navigating risks, evaluating rewards. J Healthcare Manag 2010;55(5):353-364.
10. Seigneuric R, Markey L, Nuyten DS, et al. From nanotechnology to nanomedicine: Applications to cancer research. Curr Mol Med 2010;10(7):640-652.
11. Morigi V, Tocchio A, Pellegrini CB. Nanotechnology in medicine: From inception to market domination. J Drug Deliv, March 7, 2012.
12. Bawa R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnol Law Business 2008;5(2):135-155.
13. Poirot-Mazères I. Legal aspects of the risks raised by nanotechnologies in the field of medicine. J Int Bioethique 2011;22(1):99-118, 212.
14. Nanotechnology. FDA Science & Research. Available at: www.fda. gov/ScienceResearch/SpecialTopics/Nanotechnology/default. htm. Accessed July 2, 2012.
15. Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. Int J Nanomed 2011;6:1463-1473.
16. Current Medical Applications. The Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars. Available at: www.nanotechproject.org/inventories/ medicine/apps. Accessed July 2, 2012.
17. Kim B, Rutka JT, Chan W. Nanomedicine. N Engl J Med 2010; 363:2434-2443.
18. Vaddiraju S, Tomazos I, Burgess DJ, et al. Emerging synergy between nanotechnology and implantable biosensors: A review. Biosens Bioelectron 2010;25(7):1553-1565.
19. Kroll A. Nanobiology-convergence of disciplines inspires great applications. Cell Mol Life Sci 2012;69(3):335-336.
20. Paradise J. The FDA, nanodrugs, and implications for healthcare. Presented at the American Society of Law, Medicine & Ethics, 32nd Annual Health Law Professors Conference, Cleveland, Ohio, June 5, 2009. Available at: www.tseed.com/aslme/conference/data/ papers/013.pdf. Accessed July 2, 2012.
21. Clinical Trials. gov. Available at www.clinicaltrials.gov. Accessed July 2, 2012.
22. 510k Premarket Notification Database. FDA. Available at: www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. Accessed July 2, 2012.
23. Tu C, Louie A. Nanoformulations for molecular MRI. Nanomed Nanobiotechnol 2012;4:448-457.
24. Gold Nanoparticle Technology. Nanosphere. Available at: www.nanosphere. us/page/gold-nanoparticle-technology. Accessed July 2, 2012.
25. Verigene Products. Available at: www.nanosphere.us/products. Accessed July 2, 2012.
26. National Institutes of Health, National Cancer Institute, Alliance for Nanotechnology in Cancer. Nanotechnology in Clinical Trials. Available at: http://nano.cancer.gov/learn/now/clinical-trials.asp. Accessed July 2, 2012.
27. Bind Biosciences publishes data on BIND-014, April 4, 2012. Bind Biosci Available at: www.bindbio.com/content/pages/news/ news_detail.jsp/q/news-id/71. Accessed July 2, 2012.
28. Pilot Study of AuroLase Therapy in Refractory and/or Recurrent Tumors of the Head and Neck. Available at: http://clinicaltrials. gov/ct2/show/NCT00848042?term=auroshell&rank=1. Accessed September 4, 2012.
29. AuroShell Therapy. Nanospectra. Available at: www.nanospectra. com/clinicians/aurolasetherapy.html. Accessed July 2, 2012.
30. Drugs@FDA. FDA. Available at: www.accessdata.fda.gov/scripts/ cder/drugsatfda. Accessed July 2, 2012.